One prospective strategy is the combination of Aβ peptides and tau protein with other biomarkers in AD pathophysiology and non-AD co-pathology, which is the foundation of the new AD diagnostic criteria at the Alzheimer’s Association International Conference® 20247. Here, MAPT is linked to Alzheimer disease.